MMSET Inhibitor

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

What will happen during the trial?

This is a Phase I, open-label, dose escalation and expansion study in adult patients with RRMM.

In the dose escalation phase (Part A), patients will be evaluated for DLTs during Cycle 1 (28 days). The KTX-1001 MTD, RP2D, and schedule will be determined.

In the dose expansion phase (Part B), patients with translocation t(4;14) or a GOF mutation in MMSET (eg, E1099K) will be enrolled. Patients will receive KTX-1001 at the RP2D to further define safety and tolerability and provide preliminary efficacy information.

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
60 patients (estimated)
Sponsors
K36 Therapeutics
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1334
NCT Identifier
NCT05651932

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.